The treatment of severe tetanus generally requires prolonged mechanical ventilation. We describe two cases managed with continuous intrathecal infusion of baclofen via a subcutaneous tunnelled spinal catheter and an abdominal injection port. Baclofen, by diminishing spasms and spasticity, allowed reduced sedation and paralysis requirements. This potentially decreases the time and resources required for intensive care management. Complications include sedation, hypotension and CSF infection. After appropriate dose adjustment, baclofen improves the management of severe tetanus.
Severe tetanus generally requires intensive care support and prolonged mechanical ventilation. The use of baclofen by intrathecal infusion relieves spacticity and spasms while preserving voluntary muscle function and respiratory drive 1 . The need for prolonged intensive care support may be reduced. Our experience with two cases is described.
CASE HISTORIES Case 1
A 79-year-old man suffered a penetrating injury to his right foot from a bone. His only previous adult diphtheria and tetanus vaccination (ADT) had been five years earlier. He presented to a regional hospital eight days following the injury complaining of abdominal pain, constipation, stiffness and "cramping" of the right leg. There was cellulitis of the right leg. A clinical diagnosis of tetanus was made. He was commenced on penicillin and metronidazole. Tetanus immune globulin 250 U intramuscularly and 4000 U intravenously were given. On the fifth inpatient day, the foot was debrided. The same day, transfer was made to a regional tertiary hospital following mechanical ventilation for nosocomial pneumonia for which ceftriaxone was added. He was sedated with morphine and midazolam. The right leg was hypertonic, but the knee could be fully mobilized. Movement induced right leg spasm. By day eight of admission (16 days from injury), extensor spasms on stimulation and hypertonicity involved both upper and lower limbs. The knees could only move through 20 degrees of flexion. His course was complicated by progressive hypertension to 190/100 mmHg without cardiovascular instability and a colonic pseudo-obstruction. The midazolam and morphine infusion rates were increased.
Ten days following hospital admission, a 750 µg bolus of baclofen was given by lumbar puncture. Midazolam 10 mg for increased spasms was administered just prior to the lumbar puncture to aid positioning. Generalized flaccidity developed within one hour. Four hours after the intrathecal injection, hypotension developed requiring an adrenaline infusion to a peak 0.05 µg/kg/min to maintain a mean arterial pressure greater than 70 mmHg. This was weaned over the next 12 hours. The flaccidity remained for 36 hours post injection when increased tone to passive movement was noted (worse in the lower limbs) but full joint movement ranges were possible.
An intrathecal catheter with access port was placed under general anaesthesia in the operating theatre on day 14. A 19 gauge catheter was inserted to 10 cm using an L3/4 paraspinal access to the intrathecal space. The catheter was tunnelled to the anterior abdominal wall and secured to the access port.
Sixteen days following admission, hypertonicity continued with upper and lower limbs spasms on stimulation. Hypertension to 200/120 mmHg had recurred. Morphine and midazolam by infusion were recommenced. A 250 µg bolus of baclofen followed by an infusion of 750 µg over 24 hours in a 7.5 ml volume was commenced through the injection port using a Graseby infusion pump (MS16A). There was improved tone within one hour and no further spasms noted that day. Hypotension recurred to 80/50 mmHg requiring fluid boluses. The midazolam and morphine were ceased. Access to the injection port was changed every 48 hours with surveillance cultures taken of the CSF with each new access. Nineteen days after admission, the baclofen was weaned to 200 µg/day. He was extubated on day 21 of admission. On day 22, the baclofen was reduced to 50 µg/day and ceased on day 23. Twenty-four hours after ceasing the infusion, hypertonicity and mild hyperreflexia with clonus of right leg was noted. The infusion was recommenced at 200 µg/day. Discharge to ward care was made after 26 days. The baclofen infusion was reduced to 100 µg on day 28 and then weaned at a rate of 25 µg every three days. Forty days following admission, the baclofen was ceased. The port was removed. Discharge was made home to independent living the next day. A primary vaccination schedule was completed as an outpatient.
Case 2
A 79-year-old woman presented with inability to swallow following a cut to her right leg from soilcontaminated wet roofing iron five days prior to admission. She had never received primary tetanus immunization. She received 500 U tetanus immune globulin IV. The wound was irrigated and debrided. Clinical examination noted trismus and some neck stiffness. Increased tone of upper and lower limbs was present. The blood pressure was 150/90 mmHg. She was admitted to the intensive care unit.
A lumbar puncture found clear CSF and 250 U of tetanus immune globulin was given intrathecally. Urgent intubation eight hours after intensive care admission was required for severe spasms associated with bradycardia to 20/min and marked arterial oxygen desaturation. Episodic hypotension associated with the spasms required adrenaline support, sedation with morphine and intermittent paralysis with vecuronium. Aspiration pneumonia and recurrent lateral T wave inversion on the cardiograph in the absence of a rise in creatinine kinase complicated her course. Cardiovascular instability persisted. A tracheostomy was performed on day 11 of admission. Her GCS was 3. Sedative medication was withdrawn.
On day 17, 600 µg baclofen was administered intrathecally. Her blood pressure fell from 140/70 to 68/45 mmHg over the next hour. This responded to fluid loading. The spasms and hypertonicity resolved within the hour after injection. Thirty-eight hours following the baclofen, the hypertonicity and spasms returned.
An intrathecal tunnelled catheter was inserted in the intensive care unit and a subcutaneous injection port positioned over the anterior abdominal wall on day 18. A 600 µg bolus of intrathecal baclofen followed by an infusion of 700 µg per day was commenced on day 19. Flaccidity developed within one hour. Hypotension recurred but responded to fluid boluses. By day 21 of admission, a CSF infection with methicillin resistant Staphylococcus aureus (MRSA) developed associated with a fever to 39°C and erythema around the catheter site and injection port. The baclofen was ceased and the port and intrathecal catheter removed. A CT head scan was normal. Intravenous vancomycin was commenced. Her fever settled within 48 hours. The CSF white cell count was 480∞10 6 /l with 82% polymorphs, glucose 3.6 mmol/l, protein of 490 mg/l and +1 MRSA at the time of infection. A repeated CSF culture 24 hours later was sterile with a white cell count of 52∞10 6 /l. Two weeks later the CSF findings were normal. The hypertonicity and spasms recurred after the cessation of the baclofen within 24 hours. She was able to obey commands by day 23 but continued to intermittently require paralysis until day 37. She was eventually discharged home after 178 days.
DISCUSSION
The current standard of care in the treatment of severe tetanus consists of early wound debridement, antibiotic treatment with penicillin or metronidazole and administration of parenteral tetanus immunoglobulin. Therapy with intrathecal immunoglobulin is controversial 2,3 . Treatment is then conservative while awaiting resolution of the effects of the toxin. Benzodiazepines, opiates and muscle relaxants may be used for prolonged periods 3 . The duration of mechanical ventilation with this scenario is generally prolonged. Most of the patients from the Western World with tetanus are elderly with no or incomplete primary vaccination 1 . Prolonged ventilation and autonomic dysfunction are tolerated poorly by this group. The mortality from tetanus may be reduced from 44% to 15% with the availability of intensive care services 4 . Modern facilities still have case fatality rates between 20 to 30% 5,6 . Ventilatory support for up to two months may be required 7 .
Our cases demonstrate the use of baclofen by intrathecal infusion to manage severe tetanus. The spasticity of tetanus is due to the toxin tetanospasmin causing presynaptic blockade of motor neurone inhibition by Renshaw cells and Ia fibres 8 . There are 30 reported cases of tetanus treated with intrathecal baclofen 1, [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . Baclofen is a GABA-B receptor agonist. Inhibition of calcium influx into pre-synaptic terminals inhibits excitatory pathways. Spinal action is responsible for the effects on spasticity. Suppression of the monosynaptic reflexes at segmental levels and gamma efferents also occurs. Polyneuronal, multiple segment pathways are less effected 20 . Intrathecal baclofen has been used for the treatment of spasticity in a variety of neurological conditions. Dosages used in other spasticity syndromes generally range from 5 to 10 µg per day 20 . It crosses the blood brain barrier poorly. Attempts to relieve symptoms of spasticity with systemic dosing result in drowsiness and hypotension. Intrathecal administration of baclofen has a half-life of 0.9 to 5 hours 21 . Dosage titration allows the relief of spasms while preserving voluntary movements and respiration. The ratio of lumbar to cervical baclofen concentrations is 4.1:1 at steady state, when given by a slow infusion at the lumbar level 22 . Intrathecal pharmacokinetics are similar to that of morphine. This distribution of response was not seen in our patient possibly due to the local lower limb involvement which remained until relatively late in his clinical course. The distribution of baclofen may explain the persistence of dysphagia and trismus and better lower limb than upper limb responses in most patients treated with intrathecal baclofen.
The most common technique described is the placement of an intrathecal tunnelled catheter at L3 or L4. This is connected to a subcutaneous injection port located conveniently over the anterior abdominal wall. Low-volume syringe drivers are used to provide continuous infusion. Non-tunnelled catheters have also been described 17, 20 . There have been no comparative studies of infection risk using external and subcutaneous ports for tetanus. Intermittent boluses have been described but required repeated lumbar punctures, an inability to easily titrate the dose to clinical effect and increased risks of overdose resulting in coma and hypotension 19 . With relative underdosing of baclofen, the recrudescence of tetanus symptoms, autonomic instability and apnoea may result in mortality before baclofen can be readministered.
Not all patients will have their symptoms relieved with baclofen 10 . Some patients will have problems with bradycardia, hypotension, hypotonia and sedation with inadequate relief of the tetanus symptoms. It is unclear whether this approach will decrease the need for mechanical ventilation 12 . Most reports describe a bolus dose between 250 and 1000 µg. This is followed by a continuous infusion between 500 and 2000 µg per day. Increased sensitivity may occur with age 12, 13 . Response variation may be due to catheter position differences, higher tetanus severity score 23 , time delay to treatment and inter-individual differences in the distribution of GABA-B receptors 10, 21 . The dose of baclofen required seems to diminish with time. The reason is unclear but may represent a decreased effect of tetanospasmin. Abrupt cessation of baclofen in our first patient resulted in symptom return, but over time the dose was able to be weaned with no clinical recurrence.
Hypotonia was apparent in both our patients and perhaps much smaller bolus doses are required when treating elderly patients.
Reversible coma is described with intrathecal baclofen 10 . Sedation seems related to overdose 13 . Our second patient remained unconscious following the intrathecal baclofen. The contribution of prolonged benzodiazepine infusion prior to baclofen administration or the sedative effects of baclofen itself are unclear. Our other patient had no problems with sedation. The sedative effect of baclofen may be antagonized with flumazenil while retaining the effects on the spinal cord 12, 14 . Bradypnoea and sedation after intrathecal baclofen is described after 90 minutes to six hours 16 . The decreased conscious state is most likely due to supraspinal receptors around the fourth ventricle 13, 24 .
Our first patient could be weaned rapidly from ventilation following the use of baclofen. Fifty per cent of cases either require or continue to need mechanical ventilation. In 20% the relief is only partial and 30% have central nervous system depression from the baclofen. Dysphagia persists in all and trismus persists in 30% 12 .
Three per cent of patients using intrathecal catheters to deliver baclofen develop meningitis 20 . This seems to be a lesser problem when implantable pumps are used 20 . Repeated lumbar puncture does not avoid this and risks overdose due to the inability to titrate dose to effect 19 . Our patient's CNS infection settled rapidly with catheter removal. Her infusion port was placed under local anaesthesia with sterile preparation in the intensive care unit. Our other patient had his port placed in the operating theatre. The attention to strict aseptic conditions is no doubt important.
Treatment duration is generally about 25 days but may range between four and 54 days. When to cease the baclofen infusion is not clear. Baclofen infusions are generally stopped abruptly. The dose used is generally that found to antagonize symptoms at the commencement of the initial infusion. If recurrence of tetanus is going to occur, it generally manifests within 12 hours. Delays of up to seven days are described 12 . In these cases, it is not clear whether the primary site of infection had been excised. As such, it is recommended that weaning the infusion dose maybe more appropriate than abrupt cessation as in our case. There are no studies to recommend a definitive approach. Intrathecal baclofen effectively treats the muscle spasms while avoiding conventional sedation and muscle relaxation. There is no evidence that it shortens the duration of the disease.
CONCLUSIONS
Baclofen may be used to diminish the spasms and spasticity of tetanus. An efficient route of administration is by continuous infusion by intrathecal catheter. Recommendations for the use of intrathecal baclofen include the following 14 : 1. Use of an implanted intrathecal catheter and port rather than an external system to limit the risks of infection, although definitive recommendations are still lacking. The need for an implanted device limits the use of this technique in poorer nations where intermittent intrathecal baclofen has been used.
Check the intrathecal infusion system regularly.
CSF should be aspirated, inspected for turbidity, gram stained and cultured. Vigilance for clinical signs of meningitis is mandatory. Injection should occur without resistance. 3. Use an external pump with a low volume (1 to 10 ml/24 hours) 4. Reinsert the needle into the port according to manufacturer's recommendations or local hospital policy. There are no clear guidelines as to the frequency of access change and infection risk. We chose every 48 hours. Ensure that the site in the skin above the port is changed. 5. Increases in the daily infused dosage of baclofen should be in increments of 100 to 200 µg/24 hours to avoid the rapid development of side-effects requiring the cessation of the infusion. 6. Adjust dosage according to clinical response. The expected clinical aim is for an alert patient with adequate power, mobility and breathing spontaneously if possible. 7. Bolus injections are given only at the beginning of an infusion to speed up the onset of action.
Revision of the bolus doses may be required in the elderly. 8. Avoid the combination of central depressants such as benzodiazepines and barbiturates as these may potentiate the sedating effects of baclofen. 9. ICU monitoring at least initially is required due to the risks of sedation, bradycardia, hypotension and respiratory failure from flaccidity. Intubation maybe necessary. This approach may allow general ward management if mechanical ventilation can be avoided. There may be increased risk of CSF infection. If mechanical ventilation is still required, the use of baclofen allows a reduction in the sedation and paralysis required to manage the patient. The need for ICU support including mechanical ventilation has not been shown to be reduced.
